Products
Levket-AM Tablet
Composition: Levocetirizne 5 MG + Ambroxol 75 MG + Montelukast 10 MG Tablets
Packing: 10×10 Alu-Alu
Segment: Derma+G.P+Anti-Allergy
MRP: ₹990
Description
Levocetirizine 5 mg + Ambroxol 75 mg + Montelukast 10 mg Tablet is an advanced respiratory formulation designed to provide effective relief from allergic conditions, cough, bronchial congestion, and asthma-related symptoms. This combination works by controlling allergic reactions, reducing airway inflammation, and promoting mucus clearance for better breathing comfort.
Manufactured in WHO-GMP certified facilities, this tablet ensures high quality, safety, and reliable therapeutic outcomes. Due to its broad clinical usage, it is a high-demand product and an excellent addition to any pharma franchise respiratory range.
Key Benefits:
✔ Helps relieve allergic symptoms like sneezing and runny nose
✔ Supports bronchial airway relaxation
✔ Promotes mucus clearance and cough relief
✔ Helps manage asthma and respiratory allergies
✔ Improves breathing comfort
✔ WHO-GMP certified quality manufacturing
✔ High demand respiratory product for pharma franchise
Composition:
- Levocetirizine 5 mg – Anti-allergic agent
- Ambroxol 75 mg (SR) – Mucolytic and expectorant
- Montelukast 10 mg – Leukotriene receptor antagonist for asthma and allergy control
Indications / Uses:
- Allergic rhinitis
- Chronic cough with mucus
- Bronchial asthma
- Respiratory tract allergies
- Sinus congestion and airway inflammation
Dosage Form:
- Sustained Release Tablets
(Dosage should be taken as directed by the physician)
Packaging:
- Alu-Alu packaging
- Customizable franchise packaging available
Pharma Franchise Opportunity:
We offer Levocetirizine + Ambroxol + Montelukast Tablet Pharma Franchise with:
✅ Monopoly franchise rights
✅ WHO-GMP certified manufacturing
✅ Strong demand respiratory and allergy product
✅ Promotional and marketing support
✅ Competitive pricing with attractive business margins
This product is a valuable addition to respiratory and allergy pharma franchise portfolios, ensuring strong prescription demand and repeat market sales.
